The [52Mn]Mn-BPPA-trastuzumab showed superior tumor-to-background ratios and earlier detection of HER2 positivity compared to [52Mn]Mn-DOTAGA-p-SCN-trastuzumab, though its in vivo stability requires improvement [31]. Here, ERBB2 is linked to neoplasm.